NexGel, Inc. NXGL 深 滬
交易中 06-25 10:17:26 美东时间
0.5126
-0.027
-5.09%
華盛通- 最 高0.545
- 今 開0.525
- 成交量 18.79万股
- 最 低 0.5126
- 昨 收 0.5401
- 總市值 472.89万
- 52周最高 2.8899
- 市盈率 靜 --
- 換手率 2.04%
- 52周最低 0.4811
- 委 比 85.19%
- 總股本 922.52万
- 歷史最高 5.10
- 量 比 1.61
- 振 幅 6.00%
- 歷史最低 0.4811
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
NEXGEL, Inc., a leading provider of medical and OTC products, including ultra-gentle hydrogels, announced that CEO Adam Levy will present at the Planet MicroCap Conference in Las Vegas on June 17, 2026, at 1:30 P.M. PT in Track 3 - Da Vinci 3. Investors can schedule one-on-one meetings with Levy via Nexgel@kcsa.com. The event will also feature a live webcast accessible through the provided link.
06-04 13:00
Celularity Releases CEO Letter to Shareholders
Celularity Inc. has announced strategic adjustments to focus on placental-derived cellular therapies for longevity and age-related diseases. The company completed a transaction with NexGel, Inc., generating up to $30 million and eliminating $13 million in liabilities, allowing it to streamline operations and concentrate resources on its core programs. Celularity highlights cenplacel-L, a placental-derived cell therapy, as a key product with poten...
06-03 20:15
Nexgel CEO Adam R. Levy reports disposal of 13,000 common shares worth $7,841.10
Nexgel CEO Adam R. Levy reports disposal of 13,000 common shares worth $7,841.10 Nexgel CEO Adam R. Levy sold 13,000 common shares in open-market transactions from May 27 to May 29. Sales prices were about $0.6 per share. Levy’s direct holdings fell to 344,692 shares following the transactions. Disc
05-30 08:04
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
NEXGEL Announces Data From Randomized, 30-Patient, Single-Center IRB Clinical Study, Funded By Innovative Optics
The study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to
05-19 21:06
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
NEXGEL's hydrogel patch significantly reduces laser plume exposure during hair removal, as shown in a study published in Lasers in Surgery and Medicine. The patch achieved a 95.6% reduction in plume concentration, 37.2% hair density reduction, and lower pain scores compared to the control. Conducted by plastic surgeons at the Florida Clinical Research Center, the study highlights the patch's potential to enhance safety for both patients and pract...
05-19 13:00
NexGel Q1 2026 Earnings Call Transcript
NexGel (NASDAQ:NXGL) held its first-quarter earnings conference call on Friday....
05-16 00:25
NexGel Q1 EPS $(0.11) Misses $(0.07) Estimate, Sales $2.650M Miss $3.909M Estimate
NexGel (NASDAQ:NXGL) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 22.22 percent decrease over losses of $(0.09) per share from the same
05-15 05:30
Nexgel to report first-quarter results, host conference call
Nexgel to report first-quarter results, host conference call Nexgel to release first-quarter 2026 results May 15, 2026. Conference call set for May 15 at 12:00 p.m. ET, with webcast available via Events and Presentations . Disclaimer: This news brief was created by Public Technologies (PUBT) using g
05-12 22:27
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
NEXGEL, Inc. announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to its Board of Directors. Sequence LifeScience, led by Kieser and Harris, recently secured a $5.5 million strategic investment to acquire Celularity Inc.'s degenerative disease segment. Adam Levy, CEO of NEXGEL, highlighted the transformative impact of this partnership and welcomed the new board members, emphasizing their industry experience and strategic cont...
05-06 13:00
